68Ga-PSMA-11 PET分期对前列腺癌放疗计划的影响
结果显示,53%的患者放疗计划发生重大和/或次要改变,其中18%的患者淋巴结转移超出共识CTV,13%的患者出现骨转移并接受局部放疗。结论认为68Ga-PSMA-11 PET成像可改变放疗计划,但需前瞻性研究评估临床获益。
要点
- 68Ga-PSMA-11 PET使53%前列腺癌患者放疗计划发生改变。
- 56%患者PET显示N1/M1a病变,其中47%先前为N0。
- 18%患者淋巴结转移超出共识CTV,需调整放疗范围。
核心结论
- 68Ga-PSMA-11 PET成像导致53%的患者放疗计划发生改变。
- 需要前瞻性研究评估基于68Ga-PSMA-11 PET分期改变放疗计划的临床获益。
研究设计与样本
- 比较68Ga-PSMA-11 avid病灶位置与RTOG共识盆腔淋巴结CTV,CTV外病灶覆盖视为重大改变,CTV内病灶剂量提升视为次要改变。
主要发现
- 所有患者前列腺内均有68Ga-PSMA-11摄取。
- 6例(13%)患者PET显示骨转移,其中4例先前骨扫描阴性。
- 8例(18%)患者淋巴结转移超出共识CTV。
关键数值与推荐
- 8例(18%)患者淋巴结转移超出共识CTV。
- 6例(13%)患者有限骨转移接受局部放疗。
- 24例(53%)患者放疗计划发生重大和/或次要改变。
临床怎么用
- 对高危前列腺癌患者,68Ga-PSMA-11 PET分期可识别传统影像未发现的淋巴结和骨转移,从而调整放疗靶区和剂量。
- PET发现的CTV外病灶可导致放疗范围扩大,CTV内病灶可考虑剂量提升。
局限性
- 未评估放疗计划改变对临床结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the impact of staging 68Ga-PSMA-11 PET imaging on radiotherapy (RT) dose and volumes in patients with prostate cancer. METHODS: Forty-five patients (89% high or very high risk by NCCN criteria) who underwent 68Ga-PSMA-11 PET imaging prior to definitive treatment for prostate cancer between December 2015 and December 2016 were included. Locations of 68Ga-PSMA-11-avid lesions were compared to Radiation Therapy Oncology Group consensus pelvic nodal volumes (clinical target volume [CTV]); coverage of lesions outside the consensus CTV was considered a major change, while dose-escalation to lesions within the consensus CTV was considered a minor change. RESULTS: All patients had 68Ga-PSMA-11 PET uptake in the prostate. Twenty-five patients (56%) had N1/M1a disease on 68Ga-PSMA-11 PET scan, of whom 21 (47%) were previously N0. Six patients (13%) had bone metastases on 68Ga-PSMA-11 PET scan, of whom 4 had prior negative bone scans. Eight patients (18%) had lymph node metastases outside the consensus CTV. Twelve patients (27%) received a RT boost to nodes within the consensus CTV. Six patients (13%) had limited bone metastases treated with focal RT. Overall PSMA PET imaging resulted in major and/or minor changes to RT plans in 24 patients (53%). CONCLUSION: 68Ga-PSMA-11 PET imaging resulted in RT changes in 53% of patients. Prospective investigation is needed to evaluate the clinical benefit of RT changes based on staging 68Ga-PSMA-11 PET imaging.
引用
- Wu SY, Boreta L, Shinohara K, et al. Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. Urology. 2018. PMID: 30580002. doi:10.1016/j.urology.2018.09.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。